Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...
Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Criminals are targeting pharmacies and stealing weight-loss medication in a country with body image insecurities and where ...
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.
Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results